First leg of Sanofi/Regeneron's alirocumab ODYSSEY fuels PCSK9 hype
This article was originally published in Scrip
Executive Summary
Strong top-line data for the first Phase III trial of Sanofi and Regeneron Pharmaceuticals' leading PCSK9 inhibitor, alirocumab, are adding to the hype surrounding the novel drug class as a potential new line of treatment for hypercholesterolemia.